TY - JOUR
T1 - Different angiogenic pathways in human cervical cancers
AU - Tokumo, Keizo
AU - Kodama, Junichi
AU - Seki, Noriko
AU - Nakanishi, Yoshie
AU - Miyagi, Yasunari
AU - Kamimura, Shigehito
AU - Yoshinouchi, Mitsuo
AU - Okuda, Hiroyuki
AU - Kudo, Takafumi
N1 - Funding Information:
This work was partially supported by Grants-in Aid for Scientific Research (09771277) from the Ministry of Education, Science and Culture, Japan. We thank Ms. Kasumi Oomori for her help with histochemistry and section cutting and Dr. Adriana Dusso for assistance in the preparation of the manuscript.
PY - 1998/1
Y1 - 1998/1
N2 - Objective. The objective of this study is to clarify the association between the expression of two types angiogenic factors, vascular endothelial growth factor (VEGF) and platelet-derived endothelial cell growth factor (PD- ECGF)/thymidine phosphorylase (dThdPase) and clinicopathological features, including tumor angiogenesis, in cervical cancers. Methods. The expression of VEGF and PD-ECGF was evaluated by immunohistochemical staining of tumor specimens from 73 patients with stage Ib-IIb cervical cancer (51, squamous cell carcinoma; 19, adenocarcinoma; 3, adenosquamous carcinoma) who underwent radical hysterectomy. The microvessel density was assessed by immunostaining for factor VIII-related antigen in the most neovascularized area. Results. The microvessel density in adenocarcinomas was significantly higher than that in squamous cell carcinomas (P < 0.01). The intensity of VEGF expression in adenocarcinomas was significantly stronger than that in squamous cell carcinomas (P < 0.05). In contrast, the expression of PD-ECGF in squamous cell carcinomas was significantly higher than that in adenocarcinomas (P < 0.0001) and adenosquamous carcinomas (P < 0.01). There was an inverse relationship between VEGF expression and PD-ECGF expression among all patients studied (P < 0.001). The microvessel density was significantly correlated with the intensity of VEGF expression (P < 0.05). In contrast, there was no correlation between the microvessel density and the expression of PD-ECGF. Conclusions. The expression of VEGF appears to be involved in the promotion of angiogenesis in cervical cancers. Furthermore, we propose that angiogenic pathways may be different in different types of cervical cancers.
AB - Objective. The objective of this study is to clarify the association between the expression of two types angiogenic factors, vascular endothelial growth factor (VEGF) and platelet-derived endothelial cell growth factor (PD- ECGF)/thymidine phosphorylase (dThdPase) and clinicopathological features, including tumor angiogenesis, in cervical cancers. Methods. The expression of VEGF and PD-ECGF was evaluated by immunohistochemical staining of tumor specimens from 73 patients with stage Ib-IIb cervical cancer (51, squamous cell carcinoma; 19, adenocarcinoma; 3, adenosquamous carcinoma) who underwent radical hysterectomy. The microvessel density was assessed by immunostaining for factor VIII-related antigen in the most neovascularized area. Results. The microvessel density in adenocarcinomas was significantly higher than that in squamous cell carcinomas (P < 0.01). The intensity of VEGF expression in adenocarcinomas was significantly stronger than that in squamous cell carcinomas (P < 0.05). In contrast, the expression of PD-ECGF in squamous cell carcinomas was significantly higher than that in adenocarcinomas (P < 0.0001) and adenosquamous carcinomas (P < 0.01). There was an inverse relationship between VEGF expression and PD-ECGF expression among all patients studied (P < 0.001). The microvessel density was significantly correlated with the intensity of VEGF expression (P < 0.05). In contrast, there was no correlation between the microvessel density and the expression of PD-ECGF. Conclusions. The expression of VEGF appears to be involved in the promotion of angiogenesis in cervical cancers. Furthermore, we propose that angiogenic pathways may be different in different types of cervical cancers.
UR - http://www.scopus.com/inward/record.url?scp=0031887781&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031887781&partnerID=8YFLogxK
U2 - 10.1006/gyno.1997.4876
DO - 10.1006/gyno.1997.4876
M3 - Article
C2 - 9454658
AN - SCOPUS:0031887781
SN - 0090-8258
VL - 68
SP - 38
EP - 44
JO - Gynecologic Oncology
JF - Gynecologic Oncology
IS - 1
ER -